News | October 31, 2022
Sustaining growth momentum is key for Navin Fluorine: ICICI Securities
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
ICICI Direct expects revenue CAGR of 35.6% over FY22-FY24E mainly due to the consolidation of Viatris business and they expect EBITDA margin expansion of 230bps and earnings CAGR of 64.8% over FY22-FY24E
Aurobindo has one of the most enduring generics ecosystems among peers
Adjusted PAT declined 18.8% YoY
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
India sales grew 23.5% YoY with consolidation of Wockhardt products
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E
GSKP announced sale of its newly constructed manufacturing plant at Vemgal, Karnataka to Hetero Labs for a cash consideration of Rs1.8bn
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)